{"id":"trilostane","rwe":[{"pmid":"41802412","year":"2026","title":"Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates.","finding":"","journal":"American journal of veterinary research","studyType":"Clinical Study"},{"pmid":"41742552","year":"2026","title":"Treatment and monitoring of naturally occurring Cushing's syndrome by primary care veterinarians in selected European countries.","finding":"","journal":"Journal of veterinary internal medicine","studyType":"Clinical Study"},{"pmid":"41742496","year":"2026","title":"Risk factors associated with elevated serum canine pancreatic lipase immunoreactivity concentration in dogs with hypercortisolism.","finding":"","journal":"Journal of veterinary internal medicine","studyType":"Clinical Study"},{"pmid":"41498883","year":"2026","title":"Structure and ligand based high throughput virtual screening against 3-beta hydroxysteroid dehydrogenase type-1 for drug development to treat PCOS.","finding":"","journal":"Molecular diversity","studyType":"Clinical Study"},{"pmid":"41153881","year":"2025","title":"Effectiveness of Medical Treatment on Survivability in Canine Cushing's Syndrome: A Systematic Review and Meta-Analysis.","finding":"","journal":"Animals : an open access journal from MDPI","studyType":"Clinical Study"}],"tags":[{"label":"trilostane","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2","category":"target"},{"label":"HSD3B2","category":"gene"},{"label":"H02CA01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hypercortisolism","category":"indication"},{"label":"Bioenvision","category":"company"},{"label":"Abortifacient Agents","category":"pharmacology"},{"label":"Abortifacient Agents, Steroidal","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Bioenvision","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TRILOSTANE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:05.728715+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Trilostane","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:21:14.609983+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:13.321358+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRILOSTANE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:13.527988+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: 3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type II inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:14.609830+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200907/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:14.256884+00:00"}},"allNames":"desopan","offLabel":[],"synonyms":["trilostane","modrastane","modrefen","modrenal","desopan"],"timeline":[],"approvals":[{"date":"","orphan":false,"company":"BIOENVISION","regulator":"FDA"}],"brandName":"Desopan","ecosystem":[{"indication":"Hypercortisolism","otherDrugs":[{"name":"ketoconazole","slug":"ketoconazole","company":"Janssen Pharms"},{"name":"osilodrostat","slug":"osilodrostat","company":"Recordati Rare"},{"name":"pasireotide","slug":"pasireotide","company":"Novartis"}],"globalPrevalence":166000000}],"mechanism":{"target":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2","novelty":"First-in-class","targets":[{"gene":"HSD3B2","source":"DrugCentral","target":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2","protein":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2"}],"modality":"Small Molecule","drugClass":"trilostane","explanation":"","oneSentence":"","technicalDetail":"Desopan specifically inhibits the 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 enzyme, which is a key step in the biosynthesis of cortisol from pregnenolone. By blocking this enzyme, Desopan reduces cortisol production and helps alleviate symptoms of hypercortisolism."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Trilostane","title":"Trilostane","extract":"Trilostane, sold under the brand name Vetoryl among others, is a medication which has been used in the treatment of Cushing's syndrome, Conn's syndrome, and postmenopausal breast cancer in humans. It was withdrawn for use in humans in the United States in the 1990s but was subsequently approved for use in veterinary medicine in the 2000s to treat Cushing's syndrome in dogs. It is taken by mouth.","wiki_history":"==History==\nTrilostane was withdrawn from human use in the United States market in April 1994.\n\nTrilostane was approved in the United States in 2008 for the treatment of Cushing's disease (hyperadrenocorticism) in dogs under the brand name Vetoryl.\n\nTrilostane was the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. Only one other drug, Anipryl (veterinary brand name) selegiline, is FDA-approved to treat Cushing's disease in dogs, but only to treat uncomplicated, pituitary-dependent Cushing's. The only previous treatment for the disease was the use of mitotane (brand name Lysodren) off-label.\n\nA number of compounding pharmacies in the United States sell trilostane for dogs. Since the United States approval of Vetoryl in December 2008, compounding pharmacies are no longer able to use a bulk drug product for compounding purposes, but must prepare the compounded drug from Vetoryl.","wiki_society_and_culture":"==Society and culture==\n\n=== Legal status ===\nIn March 2024, the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Trilocur, oral suspension for dogs. In March 2024, the CVMP adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Trilorale, oral suspension for dogs. Trilocur and Trilorale were approved for medical use in the European Union in May 2024.\n\n===Generic names===\nTrilostane is the generic name of the drug and its , , , and ."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2746","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TRILOSTANE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRILOSTANE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Trilostane","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:08:34.605400","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:15.952850+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"osilodrostat","drugSlug":"osilodrostat","fdaApproval":"2020-03-06","patentExpiry":"Oct 12, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ketoconazole","drugSlug":"ketoconazole","fdaApproval":"1981-06-12","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"trilostane","indications":{"approved":[{"name":"Hypercortisolism","source":"DrugCentral","snomedId":47270006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":166000000,"prevalenceMethod":"curated","prevalenceSource":"J Endocrinol Invest, 2022 (PMID:35133616)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"osilodrostat","brandName":"osilodrostat","genericName":"osilodrostat","approvalYear":"2020","relationship":"same-class"},{"drugId":"ketoconazole","brandName":"ketoconazole","genericName":"ketoconazole","approvalYear":"1981","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01615211","phase":"PHASE2","title":"Randomized Study of Letrozole and Trilostane for Medical Abortion","status":"TERMINATED","sponsor":"Kristina Gemzell Danielsson","startDate":"2012-05","conditions":["Medical Abortion, Complete or Unspecified, Without Complication"],"enrollment":36,"completionDate":"2013-10"},{"nctId":"NCT00181597","phase":"PHASE2","title":"Trilostane for Androgen-Independent Prostate Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-03","conditions":["Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":24,"completionDate":"2006-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148218","NDDF":"002119","UNII":"L0FPV48Q5R","VUID":"4020465","CHEBI":"CHEBI:32260","VANDF":"4020465","INN_ID":"3928","RXNORM":"152068","UMLSCUI":"C0077144","chemblId":"CHEMBL1200907","ChEMBL_ID":"CHEMBL1200907","KEGG_DRUG":"D01180","DRUGBANK_ID":"DB01108","PUBCHEM_CID":"656583","SNOMEDCT_US":"25142008","IUPHAR_LIGAND_ID":"6850","MESH_SUPPLEMENTAL_RECORD_UI":"C009954"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Bioenvision","relationship":"Original Developer"}],"publicationCount":494,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H02CA01","allCodes":["H02CA01"]},"biosimilarFilings":[],"originalDeveloper":"Bioenvision","recentPublications":[{"date":"2026 Mar 9","pmid":"41802412","title":"Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates.","journal":"American journal of veterinary research"},{"date":"2026 Jan 21","pmid":"41742552","title":"Treatment and monitoring of naturally occurring Cushing's syndrome by primary care veterinarians in selected European countries.","journal":"Journal of veterinary internal medicine"},{"date":"2026 Jan 21","pmid":"41742496","title":"Risk factors associated with elevated serum canine pancreatic lipase immunoreactivity concentration in dogs with hypercortisolism.","journal":"Journal of veterinary internal medicine"},{"date":"2026 Jan 7","pmid":"41498883","title":"Structure and ligand based high throughput virtual screening against 3-beta hydroxysteroid dehydrogenase type-1 for drug development to treat PCOS.","journal":"Molecular diversity"},{"date":"2025 Oct 12","pmid":"41153881","title":"Effectiveness of Medical Treatment on Survivability in Canine Cushing's Syndrome: A Systematic Review and Meta-Analysis.","journal":"Animals : an open access journal from MDPI"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Bioenvision","companyId":"bioenvision","modality":"Small molecule","firstApprovalDate":"1984","aiSummary":"","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BIOENVISION","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"BIOENVISION","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"BIOENVISION","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"BIOENVISION","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"BIOENVISION","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"BIOENVISION","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:15.952850+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}